Moreover, CRISPR/Cas9 technology has also been reported to improve the anti-tumor effect and clinical outcome of CAR-T cells by disrupting T cell inhibitory receptors, such as PD-1 (68) and Lymphocyte activation gene-3 (LAG3) (69). This evidence concerns the gene PDCD1 and neoplasm.